UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals

Benedet, AL; Ashton, NJ; Pascoal, TA; Leuzy, A; Mathotaarachchi, S; Kang, MS; Therriault, J; ... Neto, PR; + view all (2019) Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring , 11 pp. 679-689. 10.1016/j.dadm.2019.08.002. Green open access

[img]
Preview
Text
Zetterberg_Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals_VoR.pdf - Published version

Download (1MB) | Preview

Abstract

INTRODUCTION: Neurofilament light chain (NfL) is a promising blood biomarker to detect neurodegeneration in Alzheimer's disease (AD) and other brain disorders. However, there are limited reports of how longitudinal NfL relates to imaging biomarkers. We herein investigated the relationship between blood NfL and brain metabolism in AD. METHODS: Voxelwise regression models tested the cross-sectional association between [{18}^F]fluorodeoxyglucose ([{18}^F]FDG) and both plasma and cerebrospinal fluid NfL in cognitively impaired and unimpaired subjects. Linear mixed models were also used to test the longitudinal association between NfL and ([{18}^F]FDG) in amyloid positive (Aβ+) and negative (Aβ−) subjects. RESULTS: Higher concentrations of plasma and cerebrospinal fluid NfL were associated with reduced ([{18}^F]FDG) uptake in correspondent brain regions. In Aβ+ participants, NfL associates with hypometabolism in AD-vulnerable regions. Longitudinal changes in the association ([{18}^F]FDG-Nfl) were confined to cognitively impaired (Aβ+) individuals. DISCUSSION: These findings indicate that plasma NfL is a proxy for neurodegeneration in AD-related regions in (Aβ+) subjects.

Type: Article
Title: Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.dadm.2019.08.002
Publisher version: https://doi.org/10.1016/j.dadm.2019.08.002
Language: English
Additional information: © 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
Keywords: Neurofilament light Hypometabolism [{18}^F]FDG, Neurodegeneration, Alzheimer's disease, Biomarkers, Blood, PET, Longitudinal
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10083006
Downloads since deposit
3Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item